Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle filed a Form 4 on September 1, 2026, disclosing transactions in common stock and a stock option executed on August 28, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Mittie Doyle exercised a stock option for 679 shares of common stock at an exercise price of $8.04 per share on August 28, 2026.
  • Shares sold: 679 shares of common stock were disposed of at a price of $20 per share on August 28, 2026.
  • Remaining direct ownership: Following the transactions, Doyle directly held 51,776 shares of common stock.
  • Options outstanding: Doyle retains 113,734 stock options (right to buy) with an exercise price of $8.04 and an expiration date of January 28, 2035.
  • Trading plan: Both transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Doyle on November 13, 2025.
  • Vesting schedule: The stock option vests 25% on January 28, 2026, with the remainder vesting in equal monthly installments over the following three years, subject to continued service.

Avalo Therapeutics CMO Doyle Executes Option Exercise and Sale Under 10b5-1 Plan

According to the Form 4 filed with the SEC on September 1, 2026, Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, Inc. (NASDAQ:AVTX), reported two transactions in the company's common stock dated August 28, 2026. The filing indicates both transactions were carried out under a Rule 10b5-1 trading plan that Doyle adopted on November 13, 2025.

The filing discloses that Doyle exercised a stock option (transaction code M) covering 679 shares of common stock at an exercise price of $8.04 per share, acquiring those shares. On the same date, Doyle disposed of 679 shares (transaction code S) at a price of $20 per share. Following these transactions, the filing reports Doyle's direct beneficial ownership of common stock at 51,776 shares.

In Table II, the filing records that the exercised stock option had a conversion or exercise price of $8.04 and an expiration date of January 28, 2035. The price of the derivative security at the time of exercise is listed as $0. Following the exercise, Doyle's remaining directly held stock options total 113,734. The filing notes the option vests 25% on January 28, 2026, with the remaining portion vesting in equal monthly installments over the following three years, subject to the reporting person's continued service on each vesting date. The Form 4 was signed by Christopher Sullivan as Attorney-in-Fact.

What Was Disclosed

The filing reports a same-day option exercise and share sale by Avalo Therapeutics' Chief Medical Officer on August 28, 2026, both executed under a pre-established Rule 10b5-1 plan, leaving Doyle with 51,776 shares and 113,734 stock options directly held.